🔴 Alzamend Neuro is trading 5.15% down today with no clear company-specific catalyst

Alzamend Neuro is trading 5.15% down now at $1.56, reversing the prior session’s gain; the catalyst remains unclear.

• No September 2, 2026 company-specific announcement or credible report directly explains the decline.
• Recent official updates focused on positive AL001 clinical data, financing, and upcoming conference presentations rather than adverse developments.
• Biotech is broadly higher, so sector strength does not explain the move.